MBRX insider transaction filings
Moleculin Biotech, Inc. — 22 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-05. Screen MBRX transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-05 | 4 | PICKER DONALD H — Chief Science Officer | Purchase (P): 173,333 · Purchase (P): 519,999 (derivative) | EDGAR |
| 2026-08-05 | 4 | KLEMP WALTER V — CEO and President, Director | Purchase (P): 533,333 · Grant/award (A): 1,599,999 (derivative) | EDGAR |
| 2026-08-05 | 4 | Foster Jonathan P. — Chief Financial Officer | Purchase (P): 293,333 · Purchase (P): 879,999 (derivative) | EDGAR |
| 2026-06-24 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 150 · Tax withholding (F): 37 @ $2.88 · Option exercise (M): 360 · Tax withholding (F): 88 @ $3.12 · Option exercise (M): 150 (derivative) @ $0 · Option exercise (M): 360 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 109 · Tax withholding (F): 31 @ $2.88 · Option exercise (M): 174 · Tax withholding (F): 41 @ $3.12 · Option exercise (M): 109 (derivative) @ $0 · Option exercise (M): 174 (derivative) @ $0 | EDGAR |
| 2026-06-24 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 44 · Tax withholding (F): 13 @ $2.88 · Option exercise (M): 71 · Tax withholding (F): 21 @ $3.12 · Option exercise (M): 44 (derivative) @ $0 · Option exercise (M): 71 (derivative) @ $0 | EDGAR |
| 2025-11-14 | 4 | KLEMP WALTER V — CEO and President, Director | Grant/award (A): 830,000 (derivative) · Grant/award (A): 750,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Yan Joy — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | George Robert E. — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Climaco John M — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Foster Jonathan P. — EVP & CFO | Grant/award (A): 600,000 (derivative) · Grant/award (A): 400,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | Cermak Elizabeth — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | PICKER DONALD H — CSO | Grant/award (A): 200,000 (derivative) · Grant/award (A): 200,000 (derivative) | EDGAR |
| 2025-11-14 | 4 | CANNON MICHAEL D — Director | Grant/award (A): 150,000 (derivative) | EDGAR |
| 2025-11-06 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 28,750 · Tax withholding (F): 7,001 @ $0.50 · Option exercise (M): 28,750 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 20,625 · Option exercise (M): 5,023 @ $0.50 · Option exercise (M): 20,625 (derivative) @ $0 | EDGAR |
| 2025-11-06 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 8,750 · Tax withholding (F): 2,131 @ $0.50 · Option exercise (M): 8,750 (derivative) @ $0 | EDGAR |
| 2025-06-23 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 3,750 · Tax withholding (F): 914 @ $0.27 · Option exercise (M): 8,990 · Tax withholding (F): 2,190 @ $0.27 · Purchase (P): 675,675 @ $0.37 · Option exercise (M): 3,750 (derivative) @ $0 · +2 more | EDGAR |
| 2025-06-23 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 2,711 · Tax withholding (F): 661 @ $0.27 · Option exercise (M): 4,328 · Tax withholding (F): 1,054 @ $0.27 · Purchase (P): 270,270 @ $0.37 · Option exercise (M): 2,711 (derivative) @ $0 · +2 more | EDGAR |
| 2025-06-23 | 4 | PICKER DONALD H — Chief Science Officer | Option exercise (M): 1,078 · Tax withholding (F): 263 @ $0.27 · Option exercise (M): 1,766 · Tax withholding (F): 430 @ $0.27 · Option exercise (M): 1,078 (derivative) @ $0 · Option exercise (M): 1,766 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | KLEMP WALTER V — CEO and President, Director | Option exercise (M): 1,667 · Tax withholding (F): 406 @ $0.69 · Option exercise (M): 1,667 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Foster Jonathan P. — Chief Financial Officer | Option exercise (M): 833 · Tax withholding (F): 203 @ $0.69 · Option exercise (M): 833 (derivative) @ $0 | EDGAR |
Recent 8-K events — Moleculin Biotech, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=MBRX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →